Skip to main content

Table 2 Research study design for combined mentions of point-of-care tests for a biomarker paired with a specific condition (n = 155), as identified from n = 141 research reports

From: Point-of-care tests in the emergency medical services: a scoping review

Study designs

Biomarker for conditions

Systematic review

RCT

Economic evaluation

NRSI (Comparative cohort study of interventions

Qualitative

Observation

Survey

DTA

Development

Grand Total

n(%)

n(%)

n(%)

n(%)

n(%)

n(%)

n(%)

n(%)

n(%)

n(%)

Calcium ions for cardiac arrest

      

1(0.6)

  

1(0.6)

Copeptin for ACS

       

1(0.6)

 

1(0.6)

Covid-19 antigen for Covid-19

    

1(0.6)

  

2(1.3)

 

4(2.6)

Creatine for sepsis

       

1(0.6)

 

1(0.6)

Creatine kinase for ACS

       

1(0.6)

 

3(1.9)

C-reactive protein for COPD

    

1(0.6)

1(0.6)

   

2(1.3)

H-FABP for ACS

2(1.3)

      

1(0.6)

 

3(1.9)

Glucose for diabetes

    

1(0.6)

 

1(0.6)

  

2(1.3)

Glucose for hypoglycaemia

        

1(0.6)

1(0.6)

Glucose for sepsis

       

2(1.3)

 

2(1.3)

Glucose for trauma

     

1(0.6)

   

1(0.6)

Glucose for undifferentiated conditions

     

1(0.6)

   

1(0.6)

INR for coagulopathy in trauma

1(0.6)

     

1(0.6)

3(1.9)

1(0.6)

6(3.1)

Ketone for diabetes

      

1(0.6)

  

1(0.6)

Lactate for ACD

       

1(0.6)

 

1(0.6)

Lactate for cardiac arrest

       

1(0.6)

 

1(0.6)

Lactate for coagulopathy in trauma

       

1(0.6)

 

1(0.6)

Lactate for critical illness

1(0.6)

      

8(5.0)

 

9(6.0)

Lactate for seizures

       

1(0.6)

 

1(0.6)

Lactate for sepsis

4(2.6)

  

1(0.6)

  

1(0.6)

13(8.4)

2(1.2)

21(14.0)

Lactate for trauma

4(2.6)

      

6(4.0)

1(0.6)

11(7.3)

Lactate for undifferentiated conditions

        

1(0.6)

1(0.6)

Myoglobin for ACS

       

4(2.6)

 

4(2.6)

NT-proBNP for ACS

       

1(0.6)

 

1(0.6)

NT-proBNP for heart failure

       

2(1.2)

1(0.6)

3(1.9)

NT-proBNP for sepsis

       

1(0.6)

 

1(0.6)

Panel tests for ACS

       

1(0.6)

 

1(0.6)

Panel tests for cardiac arrest

     

2(1.3)

   

2(1.3)

Panel tests for COPD

    

1(0.6)

 

1(0.6)

  

2(1.3)

Panel tests for critical illness

     

3(1.9)

  

1(0.6)

4(2.6)

Panel tests for frail elderly *

     

2(1.3)

   

2(1.3)

Panel tests for heart failure

      

1(0.6)

  

1(0.6)

Panel tests for trauma

     

1(0.6)

 

1(0.6)

 

2(1.3)

Panel tests for undifferentiated conditions

    

1(0.6)

 

1(0.6)

1(0.6)

2(1.2)

5(3.2)

Purine for stroke

       

1(0.6)

 

1(0.6)

Toxicology for drug intoxication

     

1(0.6)

   

1(0.6)

Toxicology for methanol poisoning

        

1(0.6)

1(0.6)

Troponin for ACS

5(3.2)

6(4.0)

2(1.3)

8(5.1)

 

1(0.6)

 

17(11.0)

1(0.6)

40(26.5)

Undifferentiated biomarkers and conditions

3(1.9)

    

1(0.6)

 

1(0.6)

 

5(3.2)

VHA for coagulopathy in trauma

        

4(2.6)

4(2.6)

Grand Total

22(14.2)

6(3.9)

2(1.3)

9(5.8)

5(3.2)

17(11.0)

6(3.9)

72(46.4)

16 (10.3)

155(100)

  1. Footnotes: The denominator in the table represents n = 155 instances of combined mentions of point-of-care tests for a biomarker paired with a specific condition, as identified from n = 141 research reports. RCT randomised controlled trial. NRSI (Non randomised study of intervention – comparative cohort). DTA diagnostic test accuracy study. Development (experimental study carried out either in controlled conditions e.g. in a laboratory, or using defined samples with known biomarker concentration). Qualitative, qualitative research. ACS Acute coronary syndromes ACD Acute cardiovascular disease COPD Chronic obstructive pulmonary disease, INR International Normalized Ratio, H-FABP Human-type fatty acid binding protein, NT-ProBNP N-terminal Beta-Natriuretic Peptide. VHA Viscoelastic haemostatic assay
Back to article page

Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine

ISSN: 1757-7241